| In millions, except per share items | Jul-01-23 | Apr-01-23 | Dec-31-22 | Oct-01-22 | Jul-02-22 | Apr-02-22 | Dec-31-21 | Oct-02-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Net sales | 137 | 119 | 126 | 129 | 140 | 117 | 130 | 109 |
| Net sales growth | -2.3% | 1.5% | -3.5% | 18.2% | 27.8% | 43.4% | 32.3% | |
| Cost of sales | 48 | 45 | 52 | 44 | 44 | 42 | 43 | 30 |
| Gross profit | 89 | 74 | 74 | 85 | 97 | 76 | 88 | 79 |
| Gross margin | 65.0% | 62.1% | 59.0% | 65.7% | 68.9% | 64.5% | 67.3% | 72.6% |
| Selling, general and administrative expense | 75 | 81 | 78 | 79 | 90 | 86 | 81 | 70 |
| Research and development expense | 3 | 4 | 7 | 6 | 6 | 7 | 7 | 6 |
| Restructuring costs | 1 | 0 | 5 | 1 | 1 | 1 | 1 | 2 |
| Change in fair value of contingent consideration | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 1 |
| Depreciation and amortization | 2 | 2 | 8 | 7 | 3 | 3 | 3 | 2 |
| Impairment of assets | | 79 | | 189 | | | | |
| Loss on disposal of a business | 1 | | | | | | | |
| Operating income (loss) | 7 | -92 | -25 | -201 | -3 | -21 | -3 | -1 |
| Operating margin | 4.9% | -77.3% | -20.2% | -156.1% | -2.4% | -18.3% | -2.4% | -1.0% |
| Interest expense, net | 10.6 | -9.7 | 14.9 | 9.9 | 2.6 | 1.6 | 6.8 | 1.3 |
| Other expense (income) | 0.5 | 1.6 | 9.4 | -23.3 | 0.6 | 0.4 | 0.5 | 0.8 |
| Other expense | 11.1 | -8.1 | 33.7 | -36.7 | 3.2 | 1.9 | 1.5 | 2.1 |
| Loss before income taxes | -4 | -100 | -50 | -187 | -6 | -20 | -5 | -3 |
| Income tax expense (benefit), net | 0 | 0 | -5 | -42 | 1 | -5 | -3 | -1 |
| Net loss from continuing operations | -5 | -100 | -45 | -146 | -8 | -14 | -2 | -2 |
| Loss from discontinued operations, net of tax | | -74 | | | 0 | 0 | | |
| Net loss | -5 | -174 | -45 | -146 | -8 | -15 | -2 | -2 |
| Loss attributable to noncontrolling interest - continuing operations | 1 | 20 | | | 1 | 4 | | |
| Loss attributable to noncontrolling interest - discontinued operations | | 15 | | | | | | |
| Net loss attributable to Bioventus Inc. | -4 | -139 | -32 | -108 | -7 | -11 | 0 | -1 |
| Change in foreign currency translation adjustments | 0 | 1 | 1 | -1 | -1 | -1 | 0 | 0 |
| |
| Comprehensive loss | | | | | | | | |
| Comprehensive loss attributable to noncontrolling interest - continuing operations | | | | | | | | |
| Comprehensive loss attributable to noncontrolling interest - discontinued operations | | | | | | | | |
| Comprehensive loss attributable to Bioventus Inc. | -3 | -64 | -31 | -109 | -7 | -11 | 0 | -1 |
| |
| Loss per share of Class A common stock | | | | | | | | |
| Loss per share of Class A common stock from continuing operations, basic | 0 | 0 | 0 | 0 | 0 | 0 | | 0 |
| Loss per share of Class A common stock from continuing operations, diluted | 0 | 0 | 0 | 0 | 0 | 0 | | 0 |
| Loss per share of Class A common stock from discontinuing operations, basic | | 0 | 0 | 62 | | 0 | | 42 |
| Loss per share of Class A common stock from discontinuing operations, diluted | | 0 | 0 | 62 | | 0 | | 42 |
| |
| Loss per share of class A common stock, basic (in dollars per share) | ($0.06) | ($2.24) | ($0.52) | ($1.76) | ($0.11) | ($0.19) | | ($0.03) |
| Loss per share of class A common stock, diluted (in dollars per share) | ($0.06) | ($2.24) | ($0.52) | ($1.76) | ($0.11) | ($0.19) | | ($0.03) |
| |
| Weighted-average shares of Class A common stock outstanding | | | | | | | | |
| Basic (in shares) | 63 | 62 | 61 | 62 | 61 | 60 | 45 | 42 |
| Diluted (in shares) | 63 | 62 | 61 | 62 | 61 | 60 | 45 | 42 |